{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:52Z","timestamp":1792801372220,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"crossref","award":["2023YFS0268"],"award-info":[{"award-number":["2023YFS0268"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFS0270"],"award-info":[{"award-number":["2023YFS0270"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00415-024-12856-6","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:40:43Z","timestamp":1734360043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cerebrospinal fluid tau and disease progression in early Parkinson\u2019s disease: an 8-year longitudinal study"],"prefix":"10.1007","volume":"272","author":[{"given":"Fang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-235X","authenticated-orcid":false,"given":"Yanming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"9996","key":"12856_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"issue":"4","key":"12856_CR2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, White MT, Toledo JB et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587\u2013598","journal-title":"Ann Neurol"},{"issue":"1","key":"12856_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","volume":"15","author":"BA Hijaz","year":"2020","unstructured":"Hijaz BA, Volpicelli-Daley LA (2020) Initiation and propagation of \u03b1-synuclein aggregation in the nervous system. Mol Neurodegener 15(1):19","journal-title":"Mol Neurodegener"},{"issue":"11","key":"12856_CR4","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","volume":"140","author":"G Cisbani","year":"2017","unstructured":"Cisbani G, Maxan A, Kordower JH et al (2017) Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease. Brain 140(11):2982\u20132992","journal-title":"Brain"},{"issue":"2","key":"12856_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-1809.2009.00560.x","volume":"74","author":"TL Edwards","year":"2010","unstructured":"Edwards TL, Scott WK, Almonte C et al (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74(2):97\u2013109","journal-title":"Ann Hum Genet"},{"issue":"5619","key":"12856_CR6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636\u2013640","journal-title":"Science"},{"issue":"10","key":"12856_CR7","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, Li C, Meng L et al (2022) Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain 145(10):3454\u20133471","journal-title":"Brain"},{"issue":"20","key":"12856_CR8","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.2169\/internalmedicine.0454-17","volume":"57","author":"H Takeshige","year":"2018","unstructured":"Takeshige H, Nakayama S, Nishioka K et al (2018) Marked reduction in the striatal dopamine transporter uptake during the early stage of motor symptoms in patients with the MAPT N279K mutation. Intern Med 57(20):3015\u20133019","journal-title":"Intern Med"},{"issue":"1","key":"12856_CR9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41531-024-00708-z","volume":"10","author":"M Matarazzo","year":"2024","unstructured":"Matarazzo M, P\u00e9rez-Soriano A, Vafai N et al (2024) Misfolded protein deposits in Parkinson\u2019s disease and Parkinson\u2019s disease-related cognitive impairment, a [(11)C]PBB3 study. NPJ Parkinsons Dis 10(1):96","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"12856_CR10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, Hirst WD, Federoff HJ et al (2024) Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain 147(2):444\u2013457","journal-title":"Brain"},{"issue":"1","key":"12856_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.29273","volume":"38","author":"Y Tang","year":"2023","unstructured":"Tang Y, Li L, Hu T et al (2023) In Vivo (18) F-florzolotau tau positron emission tomography imaging in Parkinson\u2019s disease dementia. Mov Disord 38(1):147\u2013152","journal-title":"Mov Disord"},{"issue":"11","key":"12856_CR12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN, Locascio JJ, Makaretz SJ et al (2016) Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol 73(11):1334\u20131341","journal-title":"JAMA Neurol"},{"issue":"3","key":"12856_CR13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-160698","volume":"55","author":"M Buongiorno","year":"2017","unstructured":"Buongiorno M, Antonelli F, Compta Y et al (2017) Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-\u03b2 and Tau in Parkinson\u2019s disease1. J Alzheimers Dis 55(3):1261\u20131272","journal-title":"J Alzheimers Dis"},{"issue":"Pt 8","key":"12856_CR14","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/aww139","volume":"139","author":"BA Gordon","year":"2016","unstructured":"Gordon BA, Friedrichsen K, Brier M et al (2016) The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 139(Pt 8):2249\u20132260","journal-title":"Brain"},{"issue":"4","key":"12856_CR15","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000004860","volume":"90","author":"R La Joie","year":"2018","unstructured":"La Joie R, Bejanin A, Fagan AM et al (2018) Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90(4):e282\u2013e290","journal-title":"Neurology"},{"issue":"9","key":"12856_CR16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","volume":"87","author":"JP Chhatwal","year":"2016","unstructured":"Chhatwal JP, Schultz AP, Marshall GA et al (2016) Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 87(9):920\u2013926","journal-title":"Neurology"},{"issue":"3","key":"12856_CR17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall S, Janelidze S, Londos E et al (2021) Plasma phospho-tau identifies Alzheimer\u2019s co-pathology in patients with lewy body disease. Mov Disord 36(3):767\u2013771","journal-title":"Mov Disord"},{"issue":"11","key":"12856_CR18","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s10072-017-3088-1","volume":"38","author":"X Hu","year":"2017","unstructured":"Hu X, Yang Y, Gong D (2017) Changes of cerebrospinal fluid A\u03b2(42), t-tau, and p-tau in Parkinson\u2019s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. Neurol Sci 38(11):1953\u20131961","journal-title":"Neurol Sci"},{"issue":"3","key":"12856_CR19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin DJ, Fedler J, Coffey CS et al (2020) Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s disease. Ann Neurol 88(3):574\u2013587","journal-title":"Ann Neurol"},{"issue":"6","key":"12856_CR20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","volume":"31","author":"S Hall","year":"2016","unstructured":"Hall S, Surova Y, \u00d6hrfelt A et al (2016) Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s Disease. Mov Disord 31(6):898\u2013905","journal-title":"Mov Disord"},{"issue":"12","key":"12856_CR21","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek K, Chowdhury S, Siderowf A et al (2018) The Parkinson\u2019s progression markers initiative (PPMI)\u2014establishing a PD biomarker cohort. Ann Clin Transl Neurol 5(12):1460\u20131477","journal-title":"Ann Clin Transl Neurol"},{"issue":"19","key":"12856_CR22","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","volume":"75","author":"JC Dalrymple-Alford","year":"2010","unstructured":"Dalrymple-Alford JC, MacAskill MR, Nakas CT et al (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717\u20131725","journal-title":"Neurology"},{"issue":"10","key":"12856_CR23","first-page":"1277","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS et al (2013) Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277\u20131287","journal-title":"JAMA Neurol"},{"issue":"6","key":"12856_CR24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang JH, Mollenhauer B, Coffey CS et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s progression markers initiative study. Acta Neuropathol 131(6):935\u2013949","journal-title":"Acta Neuropathol"},{"issue":"Suppl 7","key":"12856_CR25","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1002\/mds.10579","volume":"18","author":"W Pirker","year":"2003","unstructured":"Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):S43-51","journal-title":"Mov Disord"},{"issue":"5","key":"12856_CR26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jnnp.70.5.624","volume":"70","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Davidsson P, Tullberg M et al (2001) Both total and phosphorylated tau are increased in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 70(5):624\u2013630","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"12856_CR27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","volume":"22","author":"B Mollenhauer","year":"2006","unstructured":"Mollenhauer B, Trenkwalder C, von Ahsen N et al (2006) Beta-amlyoid 1\u201342 and tau-protein in cerebrospinal fluid of patients with Parkinson\u2019s disease dementia. Dement Geriatr Cogn Disord 22(3):200\u2013208","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"12856_CR28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) \u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230\u2013240","journal-title":"Lancet Neurol"},{"issue":"1","key":"12856_CR29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s40478-020-01072-8","volume":"8","author":"L Ibanez","year":"2020","unstructured":"Ibanez L, Bahena JA, Yang C et al (2020) Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathol Commun 8(1):196","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"12856_CR30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2015.04.027","volume":"21","author":"AL Stav","year":"2015","unstructured":"Stav AL, Aarsland D, Johansen KK et al (2015) Amyloid-\u03b2 and \u03b1-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson\u2019s disease. Parkinsonism Relat Disord 21(7):758\u2013764","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"12856_CR31","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00702-018-1893-1","volume":"125","author":"T Schirinzi","year":"2018","unstructured":"Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018) Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm (Vienna) 125(9):1373\u20131379","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"12856_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mds.23341","volume":"26","author":"MB Aerts","year":"2011","unstructured":"Aerts MB, Esselink RA, Bloem BR et al (2011) Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord 26(1):169\u2013173","journal-title":"Mov Disord"},{"key":"12856_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","volume":"6","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Farotti L, Eusebi P et al (2014) Differential role of CSF alpha-synuclein species, tau, and A\u03b242 in Parkinson\u2019s Disease. Front Aging Neurosci 6:53","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"12856_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41531-022-00431-7","volume":"8","author":"C Xiang","year":"2022","unstructured":"Xiang C, Cong S, Tan X et al (2022) A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):165","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"12856_CR35","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","volume":"26","author":"L Parnetti","year":"2011","unstructured":"Parnetti L, Chiasserini D, Bellomo G et al (2011) Cerebrospinal fluid Tau\/\u03b1-synuclein ratio in Parkinson\u2019s disease and degenerative dementias. Mov Disord 26(8):1428\u20131435","journal-title":"Mov Disord"},{"key":"12856_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jns.2017.09.039","volume":"382","author":"VC Constantinides","year":"2017","unstructured":"Constantinides VC, Paraskevas GP, Emmanouilidou E et al (2017) CSF biomarkers \u03b2-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci 382:91\u201395","journal-title":"J Neurol Sci"},{"issue":"19","key":"12856_CR37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","volume":"89","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer B, Caspell-Garcia CJ, Coffey CS et al (2017) Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89(19):1959\u20131969","journal-title":"Neurology"},{"issue":"5","key":"12856_CR38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","volume":"126","author":"J Zhang","year":"2013","unstructured":"Zhang J, Mattison HA, Liu C et al (2013) Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 126(5):671\u2013682","journal-title":"Acta Neuropathol"},{"issue":"1","key":"12856_CR39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","volume":"84","author":"S Hall","year":"2015","unstructured":"Hall S, Surova Y, \u00d6hrfelt A et al (2015) CSF biomarkers and clinical progression of Parkinson disease. Neurology 84(1):57\u201363","journal-title":"Neurology"},{"issue":"3","key":"12856_CR40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ene.12176","volume":"21","author":"KD van Dijk","year":"2014","unstructured":"van Dijk KD, Bidinosti M, Weiss A et al (2014) Reduced \u03b1-synuclein levels in cerebrospinal fluid in Parkinson\u2019s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21(3):388\u2013394","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"12856_CR41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-8993(99)01848-X","volume":"843","author":"K Arima","year":"1999","unstructured":"Arima K, Hirai S, Sunohara N et al (1999) Cellular co-localization of phosphorylated tau- and NACP\/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson\u2019s disease and in dementia with Lewy bodies. Brain Res 843(1\u20132):53\u201361","journal-title":"Brain Res"},{"issue":"3","key":"12856_CR42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00401-005-1042-4","volume":"110","author":"K Yamaguchi","year":"2005","unstructured":"Yamaguchi K, Cochran EJ, Murrell JR et al (2005) Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol 110(3):298\u2013305","journal-title":"Acta Neuropathol"},{"issue":"1","key":"12856_CR43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-002-0563-3","volume":"104","author":"JE Duda","year":"2002","unstructured":"Duda JE, Giasson BI, Mabon ME et al (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104(1):7\u201311","journal-title":"Acta Neuropathol"},{"issue":"1","key":"12856_CR44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-022-00309-x","volume":"11","author":"SC Vermilyea","year":"2022","unstructured":"Vermilyea SC, Christensen A, Meints J et al (2022) Loss of tau expression attenuates neurodegeneration associated with \u03b1-synucleinopathy. Transl Neurodegener 11(1):34","journal-title":"Transl Neurodegener"},{"issue":"1","key":"12856_CR45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neurobiolaging.2014.07.043","volume":"36","author":"C Buddhala","year":"2015","unstructured":"Buddhala C, Campbell MC, Perlmutter JS et al (2015) Correlation between decreased CSF \u03b1-synuclein and A\u03b2\u2081\u208b\u2084\u2082 in Parkinson disease. Neurobiol Aging 36(1):476\u2013484","journal-title":"Neurobiol Aging"},{"issue":"6","key":"12856_CR46","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mds.26591","volume":"31","author":"D Vilas","year":"2016","unstructured":"Vilas D, Shaw LM, Taylor P et al (2016) Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Mov Disord 31(6):906\u2013914","journal-title":"Mov Disord"},{"issue":"1","key":"12856_CR47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag A, Siddiqui UF, Anastasiou Z et al (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol 16(1):66\u201375","journal-title":"Lancet Neurol"},{"issue":"529","key":"12856_CR48","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1126\/scitranslmed.aay3069","volume":"12","author":"AA Davis","year":"2020","unstructured":"Davis AA, Inman CE, Wargel ZM et al (2020) APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med 12(529):3069","journal-title":"Sci Transl Med"},{"issue":"12","key":"12856_CR49","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/alz.12570","volume":"18","author":"A Moscoso","year":"2022","unstructured":"Moscoso A, Karikari TK, Grothe MJ et al (2022) CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimers Dement 18(12):2614\u20132626","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12856-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:44:04Z","timestamp":1738172644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12856"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12856-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was exempt from the authors\u2019 institution because this study used open data from the PPMI cohort that had been already approved by the institutional review boards of all participating institutions. Participants gave informed consent to participate in the study before taking part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"61"}}